{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:05:25Z","timestamp":1779426325770,"version":"3.53.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473187"],"award-info":[{"award-number":["82473187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J01751"],"award-info":[{"award-number":["2021J01751"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"High-level Talent Introduction Project of Fujian Cancer Hospital","award":["F2328R-GC301-01"],"award-info":[{"award-number":["F2328R-GC301-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00259-026-07787-5","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:21:05Z","timestamp":1771287665000},"page":"4532-4548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PET\/CT-based quantification of intratumoral heterogeneity for predicting pathological complete response in breast cancer patients treated with neoadjuvant chemotherapy: A multicentre study"],"prefix":"10.1007","volume":"53","author":[{"given":"Jiwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuokai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0749-568X","authenticated-orcid":false,"given":"Chuangui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"7787_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/jco.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505. https:\/\/doi.org\/10.1200\/jco.20.03399.","journal-title":"J Clin Oncol"},{"key":"7787_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","volume":"6","author":"D Yee","year":"2020","unstructured":"Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020;6:1355\u201362. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2535.","journal-title":"JAMA Oncol"},{"key":"7787_CR3","doi-asserted-by":"publisher","first-page":"e066381","DOI":"10.1136\/bmj-2021-066381","volume":"375","author":"F Conforti","year":"2021","unstructured":"Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ (Clinical Res ed). 2021;375:e066381. https:\/\/doi.org\/10.1136\/bmj-2021-066381.","journal-title":"BMJ (Clinical Res ed)"},{"key":"7787_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(13)62422-8.","journal-title":"Lancet"},{"key":"7787_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.trecan.2015.10.005","volume":"1","author":"M Zhang","year":"2015","unstructured":"Zhang M, Rosen JM. Developmental insights into breast cancer intratumoral heterogeneity. Trends Cancer. 2015;1:242\u201351. https:\/\/doi.org\/10.1016\/j.trecan.2015.10.005.","journal-title":"Trends Cancer"},{"key":"7787_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.stem.2015.08.014","volume":"17","author":"MD Brooks","year":"2015","unstructured":"Brooks MD, Burness ML, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell. 2015;17:260\u201371. https:\/\/doi.org\/10.1016\/j.stem.2015.08.014.","journal-title":"Cell Stem Cell"},{"key":"7787_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1148\/radiol.2018172462","volume":"288","author":"J Wu","year":"2018","unstructured":"Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, et al. Intratumoral spatial heterogeneity at perfusion MR imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy. Radiology. 2018;288:26\u201335. https:\/\/doi.org\/10.1148\/radiol.2018172462.","journal-title":"Radiology"},{"key":"7787_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4731349","volume":"2021","author":"K Huang","year":"2021","unstructured":"Huang K, Wu Y, Xie Y, Huang L, Liu H. Analyzing mRNAsi-related genes identifies novel prognostic markers and potential drug combination for patients with basal breast cancer. Dis Markers. 2021;2021:4731349. https:\/\/doi.org\/10.1155\/2021\/4731349.","journal-title":"Dis Markers"},{"key":"7787_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/2159-8290.cd-14-1101","volume":"5","author":"M Zhang","year":"2015","unstructured":"Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, et al. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015;5:520\u201333. https:\/\/doi.org\/10.1158\/2159-8290.cd-14-1101.","journal-title":"Cancer Discov"},{"key":"7787_CR10","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/jco.2018.79.2721","volume":"36","author":"GH Lyman","year":"2018","unstructured":"Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol. 2018;36:2647\u201355. https:\/\/doi.org\/10.1200\/jco.2018.79.2721.","journal-title":"J Clin Oncol"},{"key":"7787_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21:751\u20139. https:\/\/doi.org\/10.1038\/nm.3886.","journal-title":"Nat Med"},{"key":"7787_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits of human breast tumours","year":"2012","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412.","journal-title":"Nature"},{"key":"7787_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126504","author":"R Mir\u00f3n Mombiela","year":"2022","unstructured":"Mir\u00f3n Mombiela R, Arildskov AR, Bruun FJ, Hasselbalch LH, Holst KB, Rasmussen SH, et al. What genetics can do for oncological imaging: a systematic review of the genetic validation data used in radiomics studies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126504.","journal-title":"Int J Mol Sci"},{"key":"7787_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1078-0432.ccr-14-0990","volume":"21","author":"JP O\u2019Connor","year":"2015","unstructured":"O\u2019Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Research: Official J Am Association Cancer Res. 2015;21:249\u201357. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-0990.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"7787_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01350-2","volume":"22","author":"S Han","year":"2020","unstructured":"Han S, Choi JY. Prognostic value of (18)F-FDG PET and PET\/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2020;22:119. https:\/\/doi.org\/10.1186\/s13058-020-01350-2.","journal-title":"Breast Cancer Res"},{"key":"7787_CR16","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1007\/s00259-023-06394-y","volume":"50","author":"RD Seban","year":"2023","unstructured":"Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50:4024\u201335. https:\/\/doi.org\/10.1007\/s00259-023-06394-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR17","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1007\/s00259-019-04313-8","volume":"46","author":"L Antunovic","year":"2019","unstructured":"Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R, et al. PET\/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2019;46:1468\u201377. https:\/\/doi.org\/10.1007\/s00259-019-04313-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.breast.2018.04.018","volume":"40","author":"H Li","year":"2018","unstructured":"Li H, Yao L, Jin P, Hu L, Li X, Guo T, et al. MRI and PET\/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast. 2018;40:106\u201315. https:\/\/doi.org\/10.1016\/j.breast.2018.04.018.","journal-title":"Breast"},{"key":"7787_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07306-y","author":"Y Gao","year":"2025","unstructured":"Gao Y, Fu Z, Zhu X, Li H, Yin L, Wu C, et al. Metabolic characterization and radiomics-based composite model for breast cancer immune microenvironment types using (18)F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07306-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-020-05619-0","volume":"181","author":"T Hirakata","year":"2020","unstructured":"Hirakata T, Fujii T, Kurozumi S, Katayama A, Honda C, Yanai K, et al. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Res Treat. 2020;181:331\u20138. https:\/\/doi.org\/10.1007\/s10549-020-05619-0.","journal-title":"Breast Cancer Res Treat"},{"key":"7787_CR21","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s00259-017-3779-0","volume":"44","author":"J Huang","year":"2017","unstructured":"Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, et al. Elevated tumor-to-liver uptake ratio (TLR) from (18)F-FDG-PET\/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging. 2017;44:1958\u201368. https:\/\/doi.org\/10.1007\/s00259-017-3779-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00259-023-06150-2","volume":"50","author":"K Chen","year":"2023","unstructured":"Chen K, Wang J, Li S, Zhou W, Xu W. Predictive value of (18)F-FDG PET\/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner\/center study with external validation. Eur J Nucl Med Mol Imaging. 2023;50:1869\u201380. https:\/\/doi.org\/10.1007\/s00259-023-06150-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.39339.610000.BE","volume":"335","author":"MD Goodyear","year":"2007","unstructured":"Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. BMJ. 2007;335:624\u20135. https:\/\/doi.org\/10.1136\/bmj.39339.610000.BE.","journal-title":"BMJ"},{"key":"7787_CR24","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol"},{"key":"7787_CR25","doi-asserted-by":"publisher","first-page":"838","DOI":"10.20892\/j.issn.2095-3941.2024.0374","volume":"21","author":"J Li","year":"2024","unstructured":"Li J, Jiang Z. Chinese society of clinical oncology breast cancer (CSCO BC) guidelines in 2024: international contributions from China. Cancer Biol Med. 2024;21:838\u201343. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0374.","journal-title":"Cancer Biol Med"},{"key":"7787_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"J Natl Compr Canc Netw"},{"key":"7787_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1216289","volume":"5","author":"A Hatzioannou","year":"2016","unstructured":"Hatzioannou A, Nayar S, Gaitanis A, Barone F, Anagnostopoulos C, Verginis P. Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4(+) tumor-infiltrating lymphocytes. Oncoimmunology. 2016;5:e1216289. https:\/\/doi.org\/10.1080\/2162402x.2016.1216289.","journal-title":"Oncoimmunology"},{"key":"7787_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41416-025-02948-z","volume":"132","author":"X Lin","year":"2025","unstructured":"Lin X, Liu Z, Zhou K, Li Y, Huang G, Zhang H, et al. Intratumoral and peritumoral PET\/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC. Br J Cancer. 2025;132:558\u201368. https:\/\/doi.org\/10.1038\/s41416-025-02948-z.","journal-title":"Br J Cancer"},{"key":"7787_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1148\/radiol.2018172986","volume":"289","author":"F Liu","year":"2018","unstructured":"Liu F, Zhou Z, Samsonov A, Blankenbaker D, Larison W, Kanarek A, et al. Deep learning approach for evaluating knee MR images: achieving high diagnostic performance for cartilage lesion detection. Radiology. 2018;289:160\u20139. https:\/\/doi.org\/10.1148\/radiol.2018172986.","journal-title":"Radiology"},{"key":"7787_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00453-0","volume":"4","author":"FE Shamout","year":"2021","unstructured":"Shamout FE, Shen Y, Wu N, Kaku A, Park J, Makino T, et al. An artificial intelligence system for predicting the deterioration of COVID-19 patients in the emergency department. NPJ Digit Med. 2021;4:80. https:\/\/doi.org\/10.1038\/s41746-021-00453-0.","journal-title":"NPJ Digit Med"},{"key":"7787_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34257-x","volume":"13","author":"F Shi","year":"2022","unstructured":"Shi F, Hu W, Wu J, Han M, Wang J, Zhang W, et al. Deep learning empowered volume delineation of whole-body organs-at-risk for accelerated radiotherapy. Nat Commun. 2022;13:6566. https:\/\/doi.org\/10.1038\/s41467-022-34257-x.","journal-title":"Nat Commun"},{"key":"7787_CR32","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222830","volume":"308","author":"Z Shi","year":"2023","unstructured":"Shi Z, Huang X, Cheng Z, Xu Z, Lin H, Liu C, et al. MRI-based quantification of intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer. Radiology. 2023;308:e222830. https:\/\/doi.org\/10.1148\/radiol.222830.","journal-title":"Radiology"},{"key":"7787_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00772-x","volume":"9","author":"A Keogan","year":"2025","unstructured":"Keogan A, Nguyen TNQ, Bouzy P, Stone N, Jirstrom K, Rahman A, et al. Prediction of post-treatment recurrence in early-stage breast cancer using deep-learning with mid-infrared chemical histopathological imaging. NPJ Precis Oncol. 2025;9:18. https:\/\/doi.org\/10.1038\/s41698-024-00772-x.","journal-title":"NPJ Precis Oncol"},{"key":"7787_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"key":"7787_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002711","volume":"15","author":"A Hosny","year":"2018","unstructured":"Hosny A, Parmar C, Coroller TP, Grossmann P, Zeleznik R, Kumar A, et al. Deep learning for lung cancer prognostication: a retrospective multi-cohort radiomics study. PLoS Med. 2018;15:e1002711. https:\/\/doi.org\/10.1371\/journal.pmed.1002711.","journal-title":"PLoS Med"},{"key":"7787_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14642-0","volume":"11","author":"K Aslan","year":"2020","unstructured":"Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, N\u00fa\u00f1ez NG, et al. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun. 2020;11:931. https:\/\/doi.org\/10.1038\/s41467-020-14642-0.","journal-title":"Nat Commun"},{"key":"7787_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab122","volume":"49","author":"Z Chen","year":"2021","unstructured":"Chen Z, Zhao P, Li C, Li F, Xiang D, Chen YZ, et al. IlearnPlus: a comprehensive and automated machine-learning platform for nucleic acid and protein sequence analysis, prediction and visualization. Nucleic Acids Res. 2021;49:e60. https:\/\/doi.org\/10.1093\/nar\/gkab122.","journal-title":"Nucleic Acids Res"},{"key":"7787_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001961","volume":"13","author":"R Natrajan","year":"2016","unstructured":"Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, et al. Microenvironmental heterogeneity parallels breast cancer progression: a histology-genomic integration analysis. PLoS Med. 2016;13:e1001961. https:\/\/doi.org\/10.1371\/journal.pmed.1001961.","journal-title":"PLoS Med"},{"key":"7787_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/19420862.2015.1007828","volume":"7","author":"O Obrezanova","year":"2015","unstructured":"Obrezanova O, Arnell A, de la Cuesta RG, Berthelot ME, Gallagher TR, Zurdo J, et al. Aggregation risk prediction for antibodies and its application to biotherapeutic development. mAbs. 2015;7:352\u201363. https:\/\/doi.org\/10.1080\/19420862.2015.1007828.","journal-title":"mAbs"},{"key":"7787_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1492494","volume":"15","author":"X Du","year":"2025","unstructured":"Du X, Chen C, Yang L, Cui Y, Li M. Preoperative prediction of recurrence risk factors in operable cervical cancer based on clinical-radiomics features. Front Oncol. 2025;15:1492494. https:\/\/doi.org\/10.3389\/fonc.2025.1492494.","journal-title":"Front Oncol"},{"key":"7787_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk2746","volume":"8","author":"A Adam-Artigues","year":"2022","unstructured":"Adam-Artigues A, Arenas EJ, Mart\u00ednez-Sabadell A, Bras\u00f3-Maristany F, Cervera R, Tormo E, et al. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Sci Adv. 2022;8:eabk2746. https:\/\/doi.org\/10.1126\/sciadv.abk2746.","journal-title":"Sci Adv"},{"key":"7787_CR42","doi-asserted-by":"publisher","unstructured":"de Souza ZS, Xavier CB, Gomes LBM, de Medeiros MFB, de Sousa MC, Pereira AAL, et al. Survival and response outcomes for Gastrointestinal neuroendocrine tumor (GEP-NETs) patients treated with Lutetium-177-DOTATATE in a Brazilian reference center: A Six-Year Follow-Up experience. Cancers. 2023;15. https:\/\/doi.org\/10.3390\/cancers15184506.","DOI":"10.3390\/cancers15184506"},{"key":"7787_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090304","author":"AL Deleu","year":"2020","unstructured":"Deleu AL, Sathekge MJ, Maes A, De Spiegeleer B, Sathekge M, de Van Wiele C. Characterization of FDG PET images using texture analysis in tumors of the gastro-intestinal tract: a review. Biomedicines. 2020. https:\/\/doi.org\/10.3390\/biomedicines8090304.","journal-title":"Biomedicines"},{"key":"7787_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"7787_CR45","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00259-014-2770-2","volume":"41","author":"KE Pengel","year":"2014","unstructured":"Pengel KE, Koolen BB, Loo CE, Vogel WV, Wesseling J, Lips EH, et al. Combined use of 18F-FDG PET\/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1515\u201324. https:\/\/doi.org\/10.1007\/s00259-014-2770-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR46","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1097\/rlu.0000000000001191","volume":"41","author":"AM Garc\u00eda Vicente","year":"2016","unstructured":"Garc\u00eda Vicente AM, Amo-Salas M, Relea Calatayud F, Mu\u00f1oz S\u00e1nchez Mdel M, Pena Pardo FJ, Jim\u00e9nez Londo\u00f1o GA, et al. Prognostic role of early and End-of-Neoadjuvant treatment 18F-FDG PET\/CT in patients with breast cancer. Clin Nucl Med. 2016;41:e313\u201322. https:\/\/doi.org\/10.1097\/rlu.0000000000001191.","journal-title":"Clin Nucl Med"},{"key":"7787_CR47","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00259-020-04684-3","volume":"47","author":"P Li","year":"2020","unstructured":"Li P, Wang X, Xu C, Liu C, Zheng C, Fulham MJ, et al. <article-title update=\"added\">18F-FDG PET\/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:1116\u201326. https:\/\/doi.org\/10.1007\/s00259-020-04684-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7787_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neo.2018.10.008","volume":"21","author":"AK Syed","year":"2019","unstructured":"Syed AK, Woodall R, Whisenant JG, Yankeelov TE, Sorace AG. Characterizing trastuzumab-induced alterations in intratumoral heterogeneity with quantitative imaging and immunohistochemistry in HER2\u2009+\u2009breast cancer. Neoplasia (New York NY). 2019;21:17\u201329. https:\/\/doi.org\/10.1016\/j.neo.2018.10.008.","journal-title":"Neoplasia (New York NY)"},{"key":"7787_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cels.2020.07.004","volume":"11","author":"AE Davies","year":"2020","unstructured":"Davies AE, Pargett M, Siebert S, Gillies TE, Choi Y, Tobin SJ, et al. Systems-Level properties of EGFR-RAS-ERK signaling amplify local signals to generate dynamic gene expression heterogeneity. Cell Syst. 2020;11:161\u2013e755. https:\/\/doi.org\/10.1016\/j.cels.2020.07.004.","journal-title":"Cell Syst"},{"key":"7787_CR50","doi-asserted-by":"publisher","first-page":"17024","DOI":"10.1038\/s41598-020-73237-3","volume":"10","author":"Y Toyama","year":"2020","unstructured":"Toyama Y, Hotta M, Motoi F, Takanami K, Minamimoto R, Takase K. Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer. Sci Rep. 2020;10:17024. https:\/\/doi.org\/10.1038\/s41598-020-73237-3.","journal-title":"Sci Rep"},{"key":"7787_CR51","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ccell.2020.07.001","volume":"38","author":"BJ Drapkin","year":"2020","unstructured":"Drapkin BJ, Minna JD. Studying lineage plasticity one cell at a time. Cancer Cell. 2020;38:150\u20132. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.001.","journal-title":"Cancer Cell"},{"key":"7787_CR52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-020-1125-8","volume":"27","author":"R Wang","year":"2021","unstructured":"Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021;27:141\u201351. https:\/\/doi.org\/10.1038\/s41591-020-1125-8.","journal-title":"Nat Med"},{"key":"7787_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06052-0","volume":"9","author":"M Karaayvaz","year":"2018","unstructured":"Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018;9:3588. https:\/\/doi.org\/10.1038\/s41467-018-06052-0.","journal-title":"Nat Commun"},{"key":"7787_CR54","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1158\/1078-0432.ccr-18-3190","volume":"25","author":"Z Liu","year":"2019","unstructured":"Liu Z, Li Z, Qu J, Zhang R, Zhou X, Li L, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res. 2019;25:3538\u201347. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-3190.","journal-title":"Clin Cancer Res"},{"key":"7787_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.846775","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Cheng Z, Gong C, Zheng C, Zhang X, Wu Z, et al. Pretreatment DCE-MRI-based deep learning outperforms radiomics analysis in predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Front Oncol. 2022;12:846775. https:\/\/doi.org\/10.3389\/fonc.2022.846775.","journal-title":"Front Oncol"},{"key":"7787_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0837","volume":"9","author":"GH Su","year":"2023","unstructured":"Su GH, Xiao Y, You C, Zheng RC, Zhao S, Sun SY, et al. Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets. Sci Adv. 2023;9:eadf0837. https:\/\/doi.org\/10.1126\/sciadv.adf0837.","journal-title":"Sci Adv"},{"key":"7787_CR57","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1021\/acsnano.0c05893","volume":"15","author":"L Li","year":"2021","unstructured":"Li L, Patil D, Petruncio G, Harnden KK, Somasekharan JV, Paige M, et al. Integration of multitargeted polymer-based contrast agents with photoacoustic computed tomography: an imaging technique to visualize breast cancer intratumor heterogeneity. ACS Nano. 2021;15:2413\u201327. https:\/\/doi.org\/10.1021\/acsnano.0c05893.","journal-title":"ACS Nano"},{"key":"7787_CR58","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/s41416-024-02871-9","volume":"131","author":"S Wang","year":"2024","unstructured":"Wang S, Wang T, Guo S, Zhu S, Chen R, Zheng J, et al. Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: a double-centre pilot study. Br J Cancer. 2024;131:1613\u201322. https:\/\/doi.org\/10.1038\/s41416-024-02871-9.","journal-title":"Br J Cancer"},{"key":"7787_CR59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215\u201333. https:\/\/doi.org\/10.1038\/nrd3626.","journal-title":"Nat Rev Drug Discov"},{"key":"7787_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18640-0","volume":"11","author":"A Taber","year":"2020","unstructured":"Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat Commun. 2020;11:4858. https:\/\/doi.org\/10.1038\/s41467-020-18640-0.","journal-title":"Nat Commun"},{"key":"7787_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0240-7","volume":"5","author":"SP Fortis","year":"2017","unstructured":"Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, et al. Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. J Immunother Cancer. 2017;5:39. https:\/\/doi.org\/10.1186\/s40425-017-0240-7.","journal-title":"J Immunother Cancer"},{"key":"7787_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162876","volume":"14","author":"B Dong","year":"2023","unstructured":"Dong B, Wu Y, Zhang J, Gu Y, Xie R, He X, et al. A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer. Front Immunol. 2023;14:1162876. https:\/\/doi.org\/10.3389\/fimmu.2023.1162876.","journal-title":"Front Immunol"},{"key":"7787_CR63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218345120","volume":"120","author":"K Kokubo","year":"2023","unstructured":"Kokubo K, Hirahara K, Kiuchi M, Tsuji K, Shimada Y, Sonobe Y, et al. Thioredoxin-interacting protein is essential for memory T cell formation via the regulation of the redox metabolism. Proc Natl Acad Sci U S A. 2023;120:e2218345120. https:\/\/doi.org\/10.1073\/pnas.2218345120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7787_CR64","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7150\/ijbs.56128","volume":"17","author":"D Liu","year":"2021","unstructured":"Liu D, Vadgama J, Wu Y. Basal-like breast cancer with low TGF\u03b2 and high TNF\u03b1 pathway activity is rich in activated memory CD4 T cells and has a good prognosis. Int J Biol Sci. 2021;17:670\u201382. https:\/\/doi.org\/10.7150\/ijbs.56128.","journal-title":"Int J Biol Sci"},{"key":"7787_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.898964","volume":"12","author":"T Ouyang","year":"2022","unstructured":"Ouyang T, Kan X, Zheng C. Immune checkpoint inhibitors for advanced hepatocellular carcinoma: monotherapies and combined therapies. Front Oncol. 2022;12:898964. https:\/\/doi.org\/10.3389\/fonc.2022.898964.","journal-title":"Front Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07787-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:08:28Z","timestamp":1779422908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07787-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7787"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07787-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the institutional review boards of Fujian Medical University Cancer Hospital, Yantai Yuhuangding Hospital, Binzhou Medical University Hospital and Weihai Municipal Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}